Study guide

Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

Key Takeaways Explain This Topic AI

Perinatal asphyxia triggers a biphasic brain injury pattern consisting of acute primary energy failure during the insult, a latent phase of about 1–6 hours, and secondary energy failure driven by mitochondrial dysfunction, excitotoxicity, and seizures.

Therapeutic hypothermia (target core temperature 33.5°C for 72 hours) must be initiated within 6 hours of birth in infants ≥36 weeks gestation with objective evidence of perinatal asphyxia and moderate-to-severe hypoxic-ischemic encephalopathy.

The modified Sarnat staging system classifies HIE into Mild (Stage 1: hyperalert, no seizures, developmental risk remains), Moderate (Stage 2: lethargic, hypotonic, seizures common, abnormal aEEG, cooling indicated), and Severe (Stage 3: comatose, flaccid, absent reflexes, flat or burst-suppression aEEG, high mortality).

After 72 hours of cooling, rewarm slowly under continuous core-temperature monitoring, commonly at 0.25–0.5°C per hour according to protocol. Continue neurological and cardiorespiratory monitoring for hypotension, apnoea and recurrent seizures.

Brain magnetic resonance imaging (MRI) performed between postnatal days 4 and 7 is the gold standard for prognostication; loss of the normal T1 high-signal intensity in the posterior limb of the internal capsule (PLIC) strongly predicts severe motor impairment and cerebral palsy.

Last updated: November 2026

Etiology and Pathophysiology of Perinatal Asphyxia

Hypoxic-Ischemic Encephalopathy (HIE) is a devastating neurological syndrome resulting from acute impairment of placental gas exchange or umbilical perfusion, leading to systemic hypoxemia, hypercapnia, and metabolic acidosis.

Perinatal Sentinel Events

Perinatal asphyxia frequently occurs as a consequence of catastrophic acute intrapartum events:

Placental Disruptions: Severe abruptio placentae, extensive placenta previa with hemorrhage.

Umbilical Cord Emergencies: Cord prolapse, true tight cord knot, cord avulsion, tight nuchal cord with vascular occlusion.

Uterine and Maternal Complications: Uterine rupture (most common in women undergoing trial of labor after previous caesarean delivery), amniotic fluid embolism, maternal cardiorespiratory arrest, profound systemic hypotension.

Fetal Factors: Ruptured vasa praevia, massive fetomaternal hemorrhage, acute twin-to-twin transfusion.

The Biphasic Cascade of Hypoxic-Ischemic Injury

Brain injury in HIE does not occur as a single static event, but evolves dynamically across three distinct pathological phases: [Acute Intrapartum Insult]

  • |
  • Primary Energy Failure (Intrapartum)
  • ATP depletion, Na+/K+ pump failure
  • Cytotoxic edema, membrane depolarization
  • Glutamate excitotoxicity & Ca2+ influx
  • |
  • Resuscitation & Reperfusion
  • |
  • Latent Phase (Hours 0 - 6)
  • Transient recovery of cerebral oxidative metabolism
  • The "Therapeutic Window" (Cooling Must Begin)
  • |
  • Secondary Energy Failure (Hours 6 - 48)
  • Mitochondrial failure & Cytochrome c release
  • Apoptosis, oxidative stress, microglial activation
  • Clinical & electrographic seizures
  • |
  • Tertiary Phase (Weeks - Months)
  • Chronic neuroinflammation, glial scarring, dysmyelination

Primary Energy Failure:

Occurs during the acute hypoxic-ischemic insult itself.

Cessation of cerebral blood flow and oxygen delivery depletes high-energy phosphates ( ATP and phosphocreatine ). Without ATP, the energy-dependent Na+/K+ ATPase membrane pumps fail, causing intracellular sodium, water, and chloride accumulation, resulting in cytotoxic edema .

Neuronal membrane depolarization triggers massive presynaptic release of excitatory amino acids, particularly glutamate , while energy-dependent reuptake transporters are blocked.

Glutamate overactivates postsynaptic NMDA (N-methyl-D-aspartate) and AMPA receptors, precipitating a lethal intracellular influx of calcium .

Intracellular calcium overload activates calpains, caspases, phospholipases, endonucleases, and neuronal nitric oxide synthase, leading to acute necrotic cell death.

The Latent Phase (The Therapeutic Window):

Following successful delivery room resuscitation and restoration of cerebral perfusion, cerebral oxidative metabolism transiently and partially recovers.

Cellular high-energy phosphates normalize, and cytotoxic edema temporarily improves.

This latent phase lasts about 1–6 hours . Although the infant appears relatively stable biochemically, downstream apoptotic cascades are primed.

The Critical Window for Hypothermia: Therapeutic hypothermia must be initiated strictly within 6 hours of birth during this latent window to halt downstream neurodestructive cascades before the secondary phase commences.

Secondary Energy Failure:

Initiates between 6 and 48 hours post-insult .

Characterized by secondary mitochondrial permeabilization with opening of the mitochondrial permeability transition pore (MPTP), leakage of cytochrome c into the cytoplasm, and activation of caspase-3 apoptotic cascades.

Marked by excessive production of reactive oxygen species (ROS), peroxynitrite radicals, microglial neuroinflammation, and secondary cytotoxic edema.

Clinically, this phase is marked by progressive neurological deterioration, brain swelling, and the emergence of severe clinical and electrographic seizures .

Tertiary Phase:

Extends for weeks to months post-insult, involving ongoing low-grade neuroinflammation, astrogliosis, microglial persistence, and impaired oligodendroglial maturation with deficient myelination.

Neonatal Drug Withdrawal: An Important Differential

Neonatal opioid withdrawal follows prenatal opioid exposure and may cause irritability, tremor, increased tone, high-pitched crying, disturbed sleep, poor feeding, vomiting or diarrhoea and poor weight gain. Onset depends on the drug and can be delayed with longer-acting opioids. Consider sepsis, hypoglycaemia, hypocalcaemia and brain injury when assessing these signs; exposure history alone does not establish the diagnosis. Use serial structured assessment, such as Finnegan scoring or the functional Eat, Sleep, Console approach. Initial care emphasises supported rooming-in when medically appropriate, low stimulation, safe soothing and feeding/growth support. Persistent functionally important withdrawal despite these measures may require neonatal-supervised oral morphine or methadone with gradual weaning. Arrange family support, a safe discharge plan and developmental follow-up.

Source: Canadian Paediatric Society 2025 neonatal withdrawal guidance .

Clinical Staging: Sarnat and Sarnat Classification

Developed in 1976 and modified for modern clinical cooling trials, the Sarnat staging system stratifies neonatal encephalopathy into three clinical stages, correlating directly with electroencephalographic findings and neurodevelopmental outcomes.

  • Clinical Feature Stage 1 (Mild) Stage 2 (Moderate) Stage 3 (Severe)
  • Level of Consciousness Hyperalert, irritable, jittery Lethargic, obtunded Stuporous or comatose
  • Muscle Tone Normal or mildly hypertonic Generalized hypotonia, proximal weakness Completely flaccid
  • Posture Mild distal flexion Flexion with frog-leg posture Decerebrate or completely limp
  • Tendon Reflexes Exaggerated, brisk clonus Overactive Decreased or absent
  • Moro Reflex Exaggerated, low threshold Incomplete, weak, or absent Completely absent
  • Sucking / Swallowing Normal or hyperactive Weak or incomplete Completely absent

Autonomic System Sympathetic predominance: dilated pupils (mydriasis), tachycardia Parasympathetic predominance: constricted pupils (miosis), bradycardia, excessive secretions Both systems depressed: fixed, dilated or unequal pupils, autonomic instability

Clinical Seizures None Common (focal/multifocal clonic) Intractable seizures or electrical silence

aEEG / Conventional EEG Continuous Normal Voltage (CNV) Discontinuous (DNV) or Burst Suppression Burst Suppression (BS) or Flat Trace (FT)

Clinical Duration Resolves within <24 hours Several days to weeks Prolonged (weeks)

Prognosis & Outcomes Usually favourable; developmental impairment can occur 20% to 30% death or disability without cooling 50% to 75% mortality; severe cerebral palsy

  • Therapeutic Hypothermia NOT indicated INDICATED INDICATED
  • Therapeutic Hypothermia Protocol: Eligibility and Initiation

Therapeutic hypothermia is the standard of care for moderate-to-severe HIE. Major multicenter trials (TOBY, CoolCap, NICHD, ICE) and Cochrane systematic reviews confirmed that therapeutic hypothermia significantly reduces the combined risk of death or severe neurodevelopmental disability at 18 to 24 months (relative risk ~0.75; Number Needed to Treat [NNT] = 6 to 7 ), with persistent neurocognitive benefits demonstrated at school age (6 to 8 years).

Inclusion Criteria (ILCOR / European Guidelines)

To qualify for therapeutic hypothermia, the neonate must meet Criteria A, B, and C :

Criterion A (Gestational Maturity): Gestational age ≥36 completed weeks AND birth weight ≥1,800 g .

Criterion B (Objective Evidence of Perinatal Asphyxia): At least ONE of the following:

10-minute Apgar score ≤5 .

Continued requirement for positive pressure ventilation or endotracheal intubation at 10 minutes of life .

Severe metabolic acidosis on umbilical cord arterial blood or any neonatal blood sample within 60 minutes of birth: pH ≤7.00 OR base deficit ≥16 mmol/L .

Criterion C (Neurological Encephalopathy Assessment): Clinical moderate-to-severe encephalopathy or the seizure criterion is required:

Moderate to severe encephalopathy (Sarnat Stage 2 or 3) demonstrated by abnormalities in at least 3 of 6 clinical categories :

  • Level of consciousness
  • Spontaneous activity
  • Posture
  • Muscle tone
  • Primitive reflexes (suck or Moro)
  • Autonomic system (pupils, heart rate, or respirations)

Confirmed clinical or electrographic seizures.

Obtain aEEG/EEG promptly to support assessment and detect seizures. An abnormal background alone does not replace clinical evidence of significant encephalopathy, and unavailable monitoring must not delay cooling when the clinical criteria are clearly met.

Exclusion Criteria

Postnatal age >6 hours at cooling initiation.

Known major lethal chromosomal abnormality (e.g., trisomy 13 or 18) or major congenital brain malformations.

Intractable systemic hemorrhage refractory to blood component replacement.

Moribund infant where redirection to palliative comfort care has been decided.

Cooling Implementation

Target Temperature: Core body temperature maintained strictly at 33.5°C (acceptable range: 33.0°C to 34.0°C ).

Modality: Total body cooling using a servo-controlled thermal mattress with circulating fluid, guided by a continuous indwelling rectal probe (inserted 5 cm) or esophageal temperature sensor.

Duration: Exactly 72 hours of maintenance hypothermia.

Controlled Rewarming Protocol and Hazards

Following the completion of 72 hours of hypothermia, rewarming must be executed with extreme vigilance.

Rewarming Specifications

Rewarming must be slow and controlled at a rate not exceeding 0.5°C per hour .

At 0.5°C per hour , warming from 33.5°C to 36.5°C takes about 6 hours ; slower protocols take longer.

Continuous core temperature monitoring must continue throughout rewarming and for at least 24 hours post-rewarming to prevent rebound pyrexia.

Warning

Complications During Rewarming: Use a controlled, slow rate and monitor continuously for hypotension, apnoea and recurrent seizures , including electrographic seizures. If seizures emerge, urgently review treatment with the neonatal team; rewarming may need to be slowed or paused. Continue temperature surveillance after rewarming to prevent rebound hyperthermia.

Bedside Neuromonitoring and Seizure Management

Continuous neurophysiological monitoring is indispensable during therapeutic hypothermia and rewarming.

Amplitude-Integrated EEG (aEEG)

Single- or dual-channel aEEG provides continuous bedside tracking of cerebral background voltage:

Continuous Normal Voltage (CNV): Continuous background activity with lower margin >5 µV and upper margin >10 µV. Associated with favorable neurodevelopmental prognosis.

Discontinuous Normal Voltage (DNV): Discontinuous background with lower margin <5 µV and upper margin >10 µV. Indicates moderate cerebral depression.

Burst Suppression (BS): Periods of very low voltage (<2 µV) interspersed with high-amplitude bursts (>25 µV). Indicates severe encephalopathy.

Continuous Low Voltage (CLV): Continuous low-amplitude background with upper margin <10 µV and lower margin <5 µV.

Flat Trace (FT): Isoelectric trace with background constantly below 5 µV. Strongly predictive of fatal outcome or severe disability.

Sleep-Wake Cycling (SWC): Characterized by periodic broadening and narrowing of the aEEG bandwidth. The return of SWC within 36 to 48 hours is an excellent prognostic marker.

Electroclinical Dissociation

Between 50% and 70% of neonatal seizures in encephalopathic infants are purely electrographic without overt motor movements. Furthermore, administration of sedatives or initial antiepileptic drugs often abolishes clinical motor manifestations while electrical cortical seizure activity persists unabated ( electroclinical uncoupling ). Continuous aEEG or multichannel video-EEG is therefore mandatory.

Antiseizure Drug Protocol

First-Line: Phenobarbital , administered at a loading dose of 20 mg/kg IV infused slowly over 20 minutes. If seizures persist, an additional dose of 10 to 20 mg/kg may be given (up to a cumulative maximum of 40 mg/kg).

Second-Line: Levetiracetam (40 to 60 mg/kg IV) or Phenytoin / Fosphenytoin (20 mg PE/kg IV over 20 minutes under continuous ECG monitoring).

Refractory Seizures: Consider a midazolam infusion (0.1–0.4 mg/kg/hour) under intensive monitoring. Lidocaine is an alternative with continuous cardiac monitoring, but is contraindicated after phenytoin/fosphenytoin or in neonates with cardiac disease ; dosing must account for therapeutic hypothermia.

Systemic Complications and Supportive Care During Cooling

Therapeutic hypothermia impacts multiple organ systems, requiring meticulous intensive care:

Cardiovascular: Sinus bradycardia (heart rate typically 80 to 100 beats/min) is a normal, expected physiological response to hypothermia that reduces myocardial metabolic work. It does not require pacing or inotropes unless systemic perfusion is compromised or heart rate falls below 60 beats/min. Maintain mean arterial pressure (MAP) >40 mmHg.

Renal and Fluid Balance: Acute tubular necrosis and syndrome of inappropriate ADH secretion (SIADH) are common. Restrict initial maintenance fluids to 40 to 50 mL/kg/day and monitor urine output and daily electrolytes.

Hematological: Mild thrombocytopenia and prolonged coagulation times (PT/aPTT) occur because hypothermia inhibits the enzymatic kinetics of clotting cascade proteins.

Dermatological: Subcutaneous fat necrosis manifests 1 to 6 weeks after cooling as firm, indurated, erythematous or violaceous subcutaneous nodules over bony pressure areas (shoulders, buttocks). Clinicians must monitor for late-onset hypercalcemia , which can cause nephrocalcinosis and cardiac arrhythmias.

  • Neuroimaging and Prognostication
  • Cranial Ultrasound (CUS)

Performed on day 1 of life primarily to rule out pre-existing antenatal brain injury (e.g., porencephaly, established ventriculomegaly, or germinal matrix hemorrhage) that would contraindicate cooling. Serial Doppler examination of the anterior cerebral artery evaluates the Resistive Index (RI) :

R I = Peak Systolic Velocity − End Diastolic Velocity Peak Systolic Velocity RI = \frac{\text{Peak Systolic Velocity} - \text{End Diastolic Velocity}}{\text{Peak Systolic Velocity}} R I = Peak Systolic Velocity Peak Systolic Velocity − End Diastolic Velocity ​

A low RI <0.55 can reflect cerebral vasodilation and is associated with adverse outcome, but its predictive value is reduced during therapeutic hypothermia. Interpret it as one part of the clinical, EEG and MRI assessment.

Brain Magnetic Resonance Imaging (MRI)

Brain MRI is the gold standard diagnostic and prognostic imaging modality in neonatal HIE.

Optimal Timing: Postnatal Day 4 to 7 (after completion of 72 hours of hypothermia and rewarming, within the first week of life).

Why not Day 1–2? Diffusion-Weighted Imaging (DWI) abnormalities are still evolving and can underestimate the full spatial extent of cytotoxic injury.

Imaging After the First Week: Diffusion abnormalities may pseudo-normalize over the following days, including around days 8–12 in cooled infants. Conventional T1/T2 imaging and MRS remain useful; repeat MRI at 10–14 days can clarify an uncertain early scan or a mismatch with the clinical course.

Major MRI Topographical Patterns of Injury

Basal Ganglia and Thalamus (BGT) Pattern:

Mechanism: Result of acute, profound, total asphyxial events (sentinel disasters such as uterine rupture or complete cord prolapse).

Involvement: Selectively damages metabolically active deep gray matter nuclei: the ventrolateral thalami, posterior putamen, and perirolandic sensorimotor cerebral cortex.

The PLIC Sign: In healthy term neonates, the posterior limb of the internal capsule (PLIC) exhibits high signal intensity (hyperintensity) on conventional T1-weighted MRI due to mature myelination. Loss of this normal high T1 signal intensity in the PLIC is an important marker of adverse motor outcome. Assess it with the distribution and severity of other MRI lesions, MRS where available, the neurological examination and EEG evolution when counselling about prognosis.

Watershed (Parasagittal / Border-Zone) Pattern:

Mechanism: Result of prolonged, partial, insidious asphyxia accompanied by systemic hypotension.

Involvement: Affects the vascular watershed regions located between the anterior, middle, and posterior cerebral artery territories, damaging the parasagittal cerebral cortex and subcortical white matter.

Outcome: Typically spares the basal ganglia; associated with cognitive impairment, speech and language deficits, and visual-spatial dysfunction, with relatively preserved gross motor capabilities.